Replimune Group Says FDA Accepts Resubmission Of BLA For RP1 In Combination With Nivolumab For Advanced Melanoma, With August 2 Goal Date And Expects Adcom Meeting In Late July

뉴스 본문을 불러오고 있어요.

Replimune Group Says FDA Accepts Resubmission Of BLA For RP1 In Combination With Nivolumab For Advanced Melanoma, With August 2 Goal Date And Expects Adcom Meeting In Late July | 웨이프 WAPE

Replimune Group Says FDA Accepts Resubmission Of BLA For RP1 In Combination With Nivolumab For Advanced Melanoma, With August 2 Goal Date And Expects Adcom Meeting In Late July

기사 요약

관련 종목

댓글 —